Lingzhi Li

Lingzhi Li

Auto-generated profile, based on publicly available information

Lingzhi Li

Department of Neurology, School of Medicine, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 February 2021 in Cells
Verified
Journal Article
Open access
PDF file
ZHZiping Han
Ziping Han
LLLingzhi Li
Lingzhi Li
YHYuyou Huang
Yuyou Huang
HZHaiping Zhao
Haiping Zhao
YLYumin Luo
Yumin Luo
Accumulating evidence supports the role of PDZ-binding kinase (PBK)/T-lymphokine-activated killer-cell-originated protein kinase (TOPK) in mitosis and cell-cycle progression of mitotically active cells, especially proliferative malignant cells. PBK/TOPK was confirmed to be associated with the development, progression, and metastasis of malignancies. Therefore, it is a potential therapeutic target in cancer therapy. Many studies have been conducted to explore the clinical applicability of potent PBK/TOPK inhibitors. However, PBK/TOPK has also been shown to be overexpressed in normal proliferative cells, including sperm and neural precursor cells in the subventricular zone of the adult brain, as well as under pathological conditions, such as ischemic tissues, including the heart, brain, and kidney, and plays important roles in their physiological functions, including proliferation and self-renewal. Thus, more research is warranted to further our understanding of PBK/TOPK inhibitors before we can consider their applicability in clinical practice. In this study, we first review the findings, general features, and signaling mechanisms involved in the regulation of mitosis and cell cycle. We then review the functions of PBK/TOPK in pathological conditions, including tumors and ischemic conditions in the heart, brain, and kidney. Finally, we summarize the advances in potent and selective inhibitors and describe the potential use of PBK/TOPK inhibitors in clinical settings.

22 October 2020 in Clinical Cardiology
Verified
Journal Article
Open access
PDF file
LLLingzhi Li
Lingzhi Li
SZShudi Zhang
Shudi Zhang
BHBing He
Bing He
XCXiaobei Chen
Xiaobei Chen
SWShihong Wang
Shihong Wang
QZQingyan Zhao
Qingyan Zhao
Background: The novel severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has spread worldwide.Hypothesis: The possible risk factors that lead to death in critical inpatients with coronavirus disease 2019 (COVID‐19) are not yet fully understood.Methods: In this single‐center, retrospective study, we enrolled 113 critical patients with COVID‐19 from Renmin Hospital of Wuhan University between February 1, 2020 and March 15, 2020. Patients who survived or died were compared.Results: A total of 113 critical patients with COVID‐19 were recruited; 50 (44.3%) died, and 63 (55.7%) recovered. The proportion of patients with ventricular arrhythmia was higher in the death group than in the recovery group (P = .021) and was higher among patients with myocardial damage than patients without myocardial damage (P = .013). Multivariate analysis confirmed independent predictors of mortality from COVID‐19: age > 70 years (HR 1.84, 95% CI 1.03‐3.28), initial neutrophil count over 6.5 × 109/L (HR 3.43, 95% CI 1.84‐6.40), C‐reactive protein greater than 100 mg/L (HR 1.93, 95% CI 1.04‐3.59), and lactate dehydrogenase over 300 U/L (HR 2.90, 95% CI 1.26‐6.67). Immunoglobulin treatment (HR 0.39, 95% CI 0.21‐0.73) can reduce the risk of death. Sinus tachycardia (HR 2.94, 95% CI 1.16‐7.46) and ventricular arrhythmia (HR 2.79, 95% CI 1.11‐7.04) were independent ECG risk factors for mortality from COVID‐19.Conclusions: Old age (>70 years), neutrophilia, C‐reactive protein greater than 100 mg/L and lactate dehydrogenase over 300 U/L are high‐risk factors for mortality in critical patients with COVID‐19. Sinus tachycardia and ventricular arrhythmia are independent ECG risk factors for mortality from COVID‐19.

1 May 2021 in Cells
Verified
Journal Article
Open access
PDF file
LLLingzhi Li
Lingzhi Li
PLPing Liu
Ping Liu
RWRongliang Wang
Rongliang Wang
YHYuyou Huang
Yuyou Huang
JLJichang Luo
Jichang Luo
YLYumin Luo
Yumin Luo
Understanding asymptomatic moyamoya disease (aMMD), for which treatment options are currently limited, is key to the development of therapeutic strategies that will slow down the progression of this disease, as well as facilitate the discovery of therapeutic targets for symptomatic MMD. Newly found transfer RNA-derived small RNAs (tsRNAs) perform potential regulatory functions in neovascularization, which is a well-known pathological manifestation of MMD. In this study, the neutrophilic tsRNA transcriptome in aMMD was profiled using next-generation RNA sequencing in five patients and five matched healthy subjects. A negative binominal generalized log-linear regression was used to identify differentially expressed (DE)-tsRNAs in aMMD. Gene Ontology and functional pathway analyses were used to identify biological pathways involved with the targeted genes of the DE-tsRNAs. Four tsRNAs were selected and validated using quantitative reverse transcription polymerase chain reaction. In total, 186 tsRNAs were DE between the two groups. Pathophysiological events, including immune response, angiogenesis, axon guidance, and metabolism adjustment, were enriched for the DE-tsRNAs. The expression levels of the four DE-tsRNAs were consistent with those in the neutrophilic transcriptome. These aberrantly expressed tsRNAs and their targeted pathophysiological processes provide a basis for potential future interventions for aMMD.

28 August 2021 in Neural Plasticity
Verified
Journal Article
Open access
PDF file
YZYangmin Zheng
Yangmin Zheng
YHYuyou Huang
Yuyou Huang
LLLingzhi Li
Lingzhi Li
PWPingping Wang
Pingping Wang
RWRongliang Wang
Rongliang Wang
YLYumin Luo
Yumin Luo
Several clinical parameters and biomarkers have been proposed as prognostic markers for stroke. However, it has not been clarified whether the risk factors affecting the prognosis of patients with recurrent and first-ever stroke are similar. In this study, we aimed to explore the relationship between soluble lectin-like oxidized low-density lipoprotein receptor 1 (sLOX-1) levels and the prediction of the functional outcome in patients with recurrent and first-ever stroke. A total of 266 patients with recurrent and first-ever stroke, who underwent follow-up for 3 months, were included in this study. Plasma samples were collected within 24 h after onset. The results showed that biomarkers for the prognosis of patients with recurrent stroke were different from that of those with first-ever stroke. sLOX-1 levels were correlated with modified Rankin Scale scores of patients with recurrent stroke alone ( , ). sLOX-1 levels were also associated with an increased risk of unfavorable outcomes in patients with recurrent stroke with an adjusted odds ratio of 1.489 (95% confidence interval, 1.204–1.842, ). Combining the risk factors showed greater accuracy for prognosis, yielding a sensitivity of 93.2% and a specificity of 75%, with an area under the curve of 0.916, evaluated by the receiver operating characteristic curve. These findings suggest that the diagnosis and prognosis are different between patients with recurrent stroke and those with first-ever stroke, and sLOX-1 level is an independent prognostic marker in patients with recurrent stroke.

5 September 2023 in Journal of the American Heart Association
Verified
Journal Article
Open access
YHYuyou Huang
Yuyou Huang
SGShanshan Gu
Shanshan Gu
ZHZiping Han
Ziping Han
ZYZhenghong Yang
Zhenghong Yang
LZLiyuan Zhong
Liyuan Zhong
JLJie Lu
Jie Lu
Background: Thrombolysis and endovascular thrombectomy are the primary treatment for ischemic stroke. However, due to the limited time window and the occurrence of adverse effects, only a small number of patients can genuinely benefit from recanalization. Intraarterial injection of rtPA (recombinant tissue plasminogen activator) based on arterial thrombectomy could improve the prognosis of patients with acute ischemic stroke, but it could not reduce the incidence of recanalization‐related adverse effects. Recently, selective brain hypothermia has been shown to offer neuroprotection against stroke. To enhance the recanalization rate of ischemic stroke and reduce the adverse effects such as tiny thrombosis, brain edema, and hemorrhage, we described for the first time a combined approach of hypothermia and thrombolysis via intraarterial hypothermic rtPA. Methods and Results: We initially established the optimal regimen of hypothermic rtPA in adult rats subjected to middle cerebral artery occlusion. Subsequently, we explored the mechanism of action mediating hypothermic rtPA by probing reduction of brain tissue temperature, attenuation of blood–brain barrier damage, and sequestration of inflammation coupled with untargeted metabolomics. Hypothermic rtPA improved neurological scores and reduced infarct volume, while limiting hemorrhagic transformation in middle cerebral artery occlusion rats. These therapeutic outcomes of hypothermic rtPA were accompanied by reduced brain temperature, glucose metabolism, and blood–brain barrier damage. A unique metabolomic profile emerged in hypothermic rtPA‐treated middle cerebral artery occlusion rats characterized by downregulated markers for energy metabolism and inflammation. Conclusions: The innovative use of hypothermic rtPA enhances their combined, as opposed to stand‐alone, neuroprotective effects, while reducing hemorrhagic transformation in ischemic stroke.

17 November 2021 in Mutagenesis
Verified
Journal Article
Closed access
PDF file
JLJianfei Li
Jianfei Li
CZCheng ZHang
Cheng ZHang
LLLingzhi Li
Lingzhi Li
XHXueqin Hu
Xueqin Hu
YJYizhen Jia
Yizhen Jia
XGXihan Guo
Xihan Guo
Obese subjects have a high baseline of genotoxic stress, but the underlying mechanism is poorly understood. Given that obesity is associated with high bile acids (BA) and low folate, we aimed to determine the interactive effect of folate deficient or supplementation to the genotoxicity and cytotoxicity of BA in human colon and liver cells. NCM460 and L-02 cells were cultured in folate-deficient (22.6 nM) and replete (2260 nM) Roswell Park Memorial Institute (RPMI)-1640 medium with or without 50 μM deoxycholic acid (DCA) or lithocholic acid (LCA) for 7 days. Moreover, these cells were cultured in folate supplemented (5.65, 11.3 and 22.6 μM) and standard (2.26 μM) medium with 200 μM DCA or LCA for 7 days. Genotoxicity and cytotoxicity were measured using the cytokinesis-block micronucleus cytome assay. Our results showed that under folate-replete condition, 50 μM DCA or LCA significantly increased the rate of micronuclei (MN) in NCM460 and L-02 cells. Significantly, the MN-inducing effect of 50 μM DCA or LCA was further enhanced by folate deficiency. Interestingly, folate supplementation exerted a dose-dependent manner to significantly decrease the rates of MN, nucleoplasmic bridges, nuclear buds, apoptosis, and necrosis induced by 200 μM DCA or LCA in NCM460 and L-02 cells. In conclusion, the genotoxicity of moderate BA (50 μM) was exacerbated by folate deficiency and folate supplementation could efficiently protect cells against the genotoxicity and cytotoxicity of high BA (200 μM).